journal article·2026-04

Defect Engineering of Bi 2 S 3‐x @PDA/CuS Z‐Scheme Heterojunction for Enhanced Sonodynamic and Chemodynamic Cancer Therapy

Yufeng Feng, Yingshu Li, Xiaoxiao Yan, Nianqi Meng, Hui‐Ling Peng, Xing‐Can Shen, Cunji Gao

Small· Volume 22· Issue 23
Publisher page

Abstract

ABSTRACT Although bismuth sulfide (Bi 2 S 3 ) with a narrow bandgap shows great promise for sonodynamic therapy (SDT), its efficacy is limited by a low reactive oxygen species (ROS) quantum yield due to the rapid recombination of electron and hole pairs. Herein, a sulfur‐vacancy‐rich Bi 2 S 3‐x @PDA/CuS (BPC) Z‐scheme heterojunction is rationally designed by coating Bi 2 S 3‐x nanorods with polydopamine (PDA) (denoted as Bi 2 S 3‐x @PDA) via in situ polymerization of dopamine hydrochloride and CuS nanoparticles growing on the Bi 2 S 3‐x @PDA surface to overcome this challenge. This design synergistically integrates sulfur‐vacancy engineering and a Z‐scheme heterostructure to regulate the electronic properties of Bi 2 S 3 , dramatically enhancing charge separation and boosting ROS production for potent SDT. Crucially, the BPC heterojunction simultaneously remodels the tumor microenvironment; it functions as a Fenton‐like nanozyme to generate hydroxyl radical ( • OH) for chemodynamic therapy while using sono‐excited holes to consume overexpressed glutathione, thereby amplifying intratumoral oxidative stress. Surface functionalization with hyaluronic acid (HA) endows the final BPC@HA nanocomposite with excellent physiological stability, biocompatibility, and active cancer‐cell targeting capabilities. As a result, in vivo studies confirmed that BPC@HA dramatically suppresses tumor growth through these combined properties. This study presents a powerful paradigm for engineering multifunctional sonosensitizers that overcome both intrinsic material limitations and extrinsic biological barriers in cancer therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Advanced Nanomaterials in Catalysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory For Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China) Guangxi Key Laboratory of Chemistry and Molecular Engineering of Medicinal Resources University Engineering Research Center for Chemistry of Characteristic Medicinal Resources (Guangxi) School of Chemistry and Pharmaceutical Sciences Guangxi Normal University Guilin China

School of Electronic and Information Engineering Guangxi Normal University Guilin China

Funding

National Natural Science Foundation of China

References (67)

Show source-provided references
1. 10.1021/acs.chemrev.7b0016110.1021/acs.chemrev.7b00161 ↗
2. 10.1039/D0CS00607F10.1039/D0CS00607F ↗
3. 10.1002/anie.20190682310.1002/anie.201906823 ↗
4. 10.1002/adma.20240966310.1002/adma.202409663 ↗
5. 10.1039/C9CS00648F10.1039/C9CS00648F ↗
6. 10.1002/adma.20200321410.1002/adma.202003214 ↗
7. 10.1039/D0MH00613K10.1039/D0MH00613K ↗
8. 10.1002/adma.20220969210.1002/adma.202209692 ↗
9. 10.1126/sciadv.adm956110.1126/sciadv.adm9561 ↗
10. Polarization Engineering and Chemical Bond Reconstruction in Rare‐Earth Hexagonal Manganite via Fe3+‐Occupied B‐Site Doping for Piezocatalytic Therapy and Ferroptosis
11. 10.1002/adma.20231100210.1002/adma.202311002 ↗
12. 10.7150/thno.389910.7150/thno.3899 ↗
13. 10.1002/advs.20200217810.1002/advs.202002178 ↗
14. 10.1002/adfm.20190405610.1002/adfm.201904056 ↗
15. 10.1002/smll.20180402810.1002/smll.201804028 ↗
16. 10.1021/acsnano.8b0089910.1021/acsnano.8b00899 ↗
17. 10.1016/j.biomaterials.2020.12007510.1016/j.biomaterials.2020.120075 ↗
18. 10.1021/acs.nanolett.6b0254710.1021/acs.nanolett.6b02547 ↗
19. 10.1021/jacs.9b1022810.1021/jacs.9b10228 ↗
20. 10.1002/adfm.20190859810.1002/adfm.201908598 ↗
21. 10.1002/anie.20180566410.1002/anie.201805664 ↗
22. 10.1073/pnas.170197611410.1073/pnas.1701976114 ↗
23. 10.1002/adfm.20190795410.1002/adfm.201907954 ↗
24. 10.1002/adfm.20210313410.1002/adfm.202103134 ↗
25. 10.1002/adma.20230798010.1002/adma.202307980 ↗
26. 10.1021/acsnano.1c0428010.1021/acsnano.1c04280 ↗
27. 10.1002/adma.20200689210.1002/adma.202006892 ↗
28. 10.1021/acsnano.1c0107710.1021/acsnano.1c01077 ↗
29. 10.1021/acsnano.0c0245810.1021/acsnano.0c02458 ↗
30. 10.1002/adma.20200243910.1002/adma.202002439 ↗
31. 10.1016/j.jcis.2019.03.07710.1016/j.jcis.2019.03.077 ↗
32. 10.1016/j.bioactmat.2020.08.02310.1016/j.bioactmat.2020.08.023 ↗
33. 10.1021/nn506137n10.1021/nn506137n ↗
34. 10.1002/smll.20210183310.1002/smll.202101833 ↗
35. 10.1039/C4TA05818F10.1039/C4TA05818F ↗
36. 10.1002/anie.20171039910.1002/anie.201710399 ↗
37. 10.1021/acsnano.9b0181810.1021/acsnano.9b01818 ↗
38. 10.1002/anie.20250750210.1002/anie.202507502 ↗
39. 10.1016/j.cej.2020.12401410.1016/j.cej.2020.124014 ↗
40. 10.1021/jacs.5c0117110.1021/jacs.5c01171 ↗
41. 10.1021/acsnano.1c0583410.1021/acsnano.1c05834 ↗
42. 10.1021/acsnano.7b0797410.1021/acsnano.7b07974 ↗
43. 10.1002/adma.20200138510.1002/adma.202001385 ↗
44. 10.1021/acs.chemmater.9b0410010.1021/acs.chemmater.9b04100 ↗
45. 10.1021/acsnano.2c0733810.1021/acsnano.2c07338 ↗
46. 10.1016/j.jcis.2023.04.10810.1016/j.jcis.2023.04.108 ↗
47. 10.1002/adfm.20231356910.1002/adfm.202313569 ↗
48. 10.1002/smll.20210667310.1002/smll.202106673 ↗
49. 10.1021/acssuschemeng.8b0130010.1021/acssuschemeng.8b01300 ↗
50. 10.1016/j.mtener.2021.10076510.1016/j.mtener.2021.100765 ↗
51. 10.1002/adma.20230064810.1002/adma.202300648 ↗
52. 10.1002/adfm.20241584210.1002/adfm.202415842 ↗
53. 10.1016/j.jcis.2022.10.05610.1016/j.jcis.2022.10.056 ↗
54. 10.1016/j.cej.2019.03.27210.1016/j.cej.2019.03.272 ↗
55. 10.1038/s41596‐018‐0001‐110.1038/s41596‐018‐0001‐1 ↗
56. 10.1002/adma.20230426210.1002/adma.202304262 ↗
57. 10.1002/smll.20220292110.1002/smll.202202921 ↗
58. 10.1002/pssb.20210026810.1002/pssb.202100268 ↗
59. 10.1016/j.solidstatesciences.2011.11.02510.1016/j.solidstatesciences.2011.11.025 ↗
60. 10.1002/adfm.20230081810.1002/adfm.202300818 ↗
61. 10.1016/j.apcatb.2019.03.01710.1016/j.apcatb.2019.03.017 ↗
62. 10.1002/adma.20210683810.1002/adma.202106838 ↗
63. 10.1016/j.apsusc.2018.08.08110.1016/j.apsusc.2018.08.081 ↗
64. 10.1002/anie.20191492510.1002/anie.201914925 ↗
65. 10.1002/smsc.20210011210.1002/smsc.202100112 ↗
66. 10.1021/jacs.4c0976810.1021/jacs.4c09768 ↗
67. 10.1016/j.actbio.2021.05.04110.1016/j.actbio.2021.05.041 ↗